NASDAQ$PRLD
Prelude Therapeutics Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
PRLD Q1 2024 — $400.0M revenue
Operating results for the three months ended March 31, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024. Prelude Therapeutics Inc reported Q1 2024 results. Net income of $31.4M. Headline numbers extracted from the Form 10-Q press release; narrative is light because this row was processed without an LLM call.
- Revenue: $400.0M.
- Net income: $31.4M.
- Operating income: $34K.
Headline financials
Revenue & EPS history
Prelude Therapeutics · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2024
+5.5%
Avg return
Earnings day
+6.7%
Avg return
5 days after
+6.0%
Avg return
30 days after
50%
11 / 22 earnings
Positive
+37.0%
Q4 2023
Best reaction
-8.2%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.1% | -6.7% | — | |
| Q4 2025 | +5.8% | -6.7% | +13.3% | |
| Q3 2025 | +10.7% | +22.2% | +26.7% | |
| Q1 2025 | -4.1% | -2.5% | +2.5% | |
| Q4 2024 | +4.1% | +1.7% | +14.4% | |
| Q3 2024 | -1.6% | -7.8% | -26.0% | |
| Q2 2024 | +21.6% | +2.2% | -2.0% | |
| Q1 2024 | -6.3% | -2.6% | -1.3% | |
| Q4 2023 | +37.0% | +23.1% | +40.2% | |
| Q3 2023 | +30.8% | +74.6% | +90.8% | |
| Q2 2023 | -2.1% | -4.8% | -2.4% | |
| Q1 2023 | -3.8% | +3.4% | -12.3% | |
| Q4 2022 | +9.2% | +12.0% | +35.1% | |
| Q3 2022 | -8.2% | -12.5% | -38.8% | |
| Q2 2022 | +21.7% | +32.4% | +21.2% | |
| Q1 2022 | +1.0% | +15.5% | +22.0% | |
| Q4 2021 | +16.9% | +3.1% | -16.4% | |
| Q3 2021 | -5.4% | -6.5% | -17.7% | |
| Q2 2021 | -5.3% | -5.7% | -3.4% | |
| Q1 2021 | +8.8% | +3.3% | -21.3% | |
| Q4 2020 | -2.6% | -5.4% | -41.3% | |
| Q3 2020 | -3.4% | +15.3% | +43.4% | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro